A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance

Sequencing Overview of Ewing Sarcoma: A Journey across Genomic, Epigenomic and Transcriptomic Landscapes

(2015) Laurens Sand et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Cancer genomics: why rare is valuable

(2015) Farzad Jamshidi et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Novel therapeutic options for relapsed hairy cell leukemia

(2015) Preetesh Jain et al.   LEUKEMIA & LYMPHOMA

Parallel screening for ALK, MET and ROS1 alterations in non-small cell lung cancer with implications for daily routine testing

(2015) Philipp Jurmeister et al.   LUNG CANCER

Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors

(2015) G. M. Frampton et al.   Cancer Discovery

Validation of a Manual Protocol for BRAF V600E Mutation-specific Immunohistochemistry

(2015) Hanns C. Dinges et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY

Molecular Testing and Personalized Treatment of Lung Cancer

(2015) Fotis Sampsonas et al.   Current Molecular Pharmacology

Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2014) M. Reck et al.   ANNALS OF ONCOLOGY

Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia

(2014) S. P. Treon et al.   BLOOD

International Society of Neuropathology-Haarlem Consensus Guidelines for Nervous System Tumor Classification and Grading

(2014) David N. Louis et al.   BRAIN PATHOLOGY

Clinical challenges in targeting anaplastic lymphoma kinase in advanced non-small cell lung cancer

(2014) Namrata Vijayvergia et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

ErbB Receptors as Prognostic and Therapeutic Drug Targets in Bone and Soft Tissue Sarcomas

(2014) Hongsheng Wang et al.   CANCER INVESTIGATION

The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast Cancer

(2014) Martin Filipits et al.   CLINICAL CANCER RESEARCH

"Companion Diagnostics": Has Their Time Come and Gone?

(2014) F. R. Hirsch et al.   CLINICAL CANCER RESEARCH

The Minority Report: Targeting the Rare Oncogenes in NSCLC

(2014) Caroline E. McCoach et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Combining Targeted Therapy With Immunotherapy inBRAF-Mutant Melanoma: Promise and Challenges

(2014) Siwen Hu-Lieskovan et al.   JOURNAL OF CLINICAL ONCOLOGY

Prevalence and Clinical Outcomes for Patients With ALK-Positive Resected Stage I to III Adenocarcinoma: Results From the European Thoracic Oncology Platform Lungscape Project

(2014) Fiona H. Blackhall et al.   JOURNAL OF CLINICAL ONCOLOGY

PIK3CAMutations Are Associated With Lower Rates of Pathologic Complete Response to Anti–Human Epidermal Growth Factor Receptor 2 (HER2) Therapy in Primary HER2-Overexpressing Breast Cancer

(2014) Sibylle Loibl et al.   JOURNAL OF CLINICAL ONCOLOGY

Multicenter Immunohistochemical ALK-Testing of Non–Small-Cell Lung Cancer Shows High Concordance after Harmonization of Techniques and Interpretation Criteria

(2014) Maximilian von Laffert et al.   Journal of Thoracic Oncology

Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

(2014) Grant A McArthur et al.   LANCET ONCOLOGY

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial

(2014) Jonathan Ledermann et al.   LANCET ONCOLOGY

Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: A report from the children's oncology group

(2014) Lars M. Wagner et al.   PEDIATRIC BLOOD & CANCER

Research Highlights: Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small-cell lung cancer

(2014) Carmelo Tibaldi   PHARMACOGENOMICS

Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies

(2014) C. Bettegowda et al.   Science Translational Medicine

Advances in Therapy for Pediatric Sarcomas

(2014) Aaron Weiss et al.   Current Oncology Reports

The Genomic Landscape of Pediatric Ewing Sarcoma

(2014) B. D. Crompton et al.   Cancer Discovery

Comprehensive Genomic Analysis of Rhabdomyosarcoma Reveals a Landscape of Alterations Affecting a Common Genetic Axis in Fusion-Positive and Fusion-Negative Tumors

(2014) J. F. Shern et al.   Cancer Discovery

Genomic Landscape of Ewing Sarcoma Defines an Aggressive Subtype with Co-Association of STAG2 and TP53 Mutations

(2014) F. Tirode et al.   Cancer Discovery

Recurrent Somatic Structural Variations Contribute to Tumorigenesis in Pediatric Osteosarcoma

(2014) Xiang Chen et al.   Cell Reports

Novel agents in development for advanced non-small cell lung cancer

(2014) Thomas E. Stinchcombe   Therapeutic Advances in Medical Oncology

Treating advanced melanoma: current insights and opportunities

(2014) Michael Tronnier et al.   Cancer Management and Research

A Multicenter Study Directly Comparing the Diagnostic Accuracy of Gene Expression Profiling and Immunohistochemistry for Primary Site Identification in Metastatic Tumors

(2013) Charles R. Handorf et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone

(2013) M. Gnant et al.   ANNALS OF ONCOLOGY

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

(2013) A. Goldhirsch et al.   ANNALS OF ONCOLOGY

Long-term Results of Adjuvant Imatinib Mesylate in Localized, High-Risk, Primary Gastrointestinal Stromal Tumor

(2013) Ronald P. DeMatteo et al.   ANNALS OF SURGERY

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology

(2013) Neal I. Lindeman et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

(2013) S. Hu et al.   BLOOD

The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients

(2013) P Dubsky et al.   BRITISH JOURNAL OF CANCER

Predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance

(2013) M Dietel et al.   CANCER GENE THERAPY

Adherence to imatinib therapy in patients with gastrointestinal stromal tumors

(2013) Jean-Yves Blay et al.   CANCER TREATMENT REVIEWS

Gastrointestinal Stromal Tumors

(2013) Markku Miettinen et al.   GASTROENTEROLOGY CLINICS OF NORTH AMERICA

Single-patient (n-of-1) trials: a pragmatic clinical decision methodology for patient-centered comparative effectiveness research

(2013) Naihua Duan et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Designing Transformative Clinical Trials in the Cancer Genome Era

(2013) Stefan Sleijfer et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

(2013) David R. Spigel et al.   JOURNAL OF CLINICAL ONCOLOGY

Blinded Comparator Study of Immunohistochemical Analysis versus a 92-Gene Cancer Classifier in the Diagnosis of the Primary Site in Metastatic Tumors

(2013) Lawrence M. Weiss et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Molecular Profiling Diagnosis in Unknown Primary Cancer: Accuracy and Ability to Complement Standard Pathology

(2013) F. Anthony Greco et al.   JNCI-Journal of the National Cancer Institute

Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib

(2013) M. Bos et al.   LUNG CANCER

Immunohistochemical detection of ROS1 is useful for identifying ROS1 rearrangements in lung cancers

(2013) Akihiko Yoshida et al.   MODERN PATHOLOGY

EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics

(2013) M. E. Arcila et al.   MOLECULAR CANCER THERAPEUTICS

'Basket studies' will hold intricate data for cancer drug approvals

(2013) Cassandra Willyard   NATURE MEDICINE

First FDA Authorization for Next-Generation Sequencer

(2013) Francis S. Collins et al.   NEW ENGLAND JOURNAL OF MEDICINE

Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer

(2013) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neue morphologische und molekulare Aspekte des Lungenkarzinoms

(2013) A. Warth et al.   PATHOLOGE

Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer

(2013) H. Yasuda et al.   Science Translational Medicine

Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors

(2013) E. J. Morris et al.   Cancer Discovery

VeriStrat® has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib

(2012) J L Kuiper et al.   BRITISH JOURNAL OF CANCER

Mechanisms of Resistance to Crizotinib in Patients withALKGene Rearranged Non–Small Cell Lung Cancer

(2012) Robert C. Doebele et al.   CLINICAL CANCER RESEARCH

Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative

(2012) A.-M. Tsimberidou et al.   CLINICAL CANCER RESEARCH

Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials

(2012) Carsten Bokemeyer et al.   EUROPEAN JOURNAL OF CANCER

BRCA1/2 mutations and expression: Response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer

(2012) Rebecca Byler Dann et al.   GYNECOLOGIC ONCOLOGY

Double-Hit Diffuse Large B-Cell Lymphoma

(2012) Jonathan W. Friedberg   JOURNAL OF CLINICAL ONCOLOGY

Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

(2012) Tina Marie Green et al.   JOURNAL OF CLINICAL ONCOLOGY

Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

(2012) Nathalie A. Johnson et al.   JOURNAL OF CLINICAL ONCOLOGY

BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group

(2012) Kathryn Alsop et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402

(2012) Gregory Cairncross et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951

(2012) Martin J. van den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

(2012) Axel Hauschild et al.   LANCET

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial

(2012) Annika Malmström et al.   LANCET ONCOLOGY

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial

(2012) Wolfgang Wick et al.   LANCET ONCOLOGY

Comprehensive genomic characterization of squamous cell lung cancers

(2012)   NATURE

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

(2012) Jonathan Ledermann et al.   NEW ENGLAND JOURNAL OF MEDICINE

BRCAness: Finding the Achilles Heel in Ovarian Cancer

(2012) G. Rigakos et al.   ONCOLOGIST

A Second-Generation MicroRNA-Based Assay for Diagnosing Tumor Tissue Origin

(2012) E. Meiri et al.   ONCOLOGIST

Guideline on the requirements of external quality assessment programs in molecular pathology

(2012) J. Han van Krieken et al.   VIRCHOWS ARCHIV

EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations

(2012) Erik Thunnissen et al.   VIRCHOWS ARCHIV

Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation

(2011) E. Tiacci et al.   BLOOD

Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation

(2011) L. Xi et al.   BLOOD

Targeted high throughput sequencing in clinical cancer Settings: formaldehyde fixed-paraffin embedded (FFPE) tumor tissues, input amount and tumor heterogeneity

(2011) Martin Kerick et al.   BMC Medical Genomics

NRAS mutation status is an independent prognostic factor in metastatic melanoma

(2011) John A. Jakob et al.   CANCER

Managing progressive disease in patients with GIST: Factors to consider besides acquired secondary tyrosine kinase inhibitor resistance

(2011) Shreyaskumar Patel   CANCER TREATMENT REVIEWS

A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors

(2011) Martin Filipits et al.   CLINICAL CANCER RESEARCH

Validation and Reproducibility of a Microarray-Based Gene Expression Test for Tumor Identification in Formalin-Fixed, Paraffin-Embedded Specimens

(2011) Raji Pillai et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification

(2011) Sai-Hong Ignatius Ou et al.   Journal of Thoracic Oncology

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

(2011) Alice T Shaw et al.   LANCET ONCOLOGY

Molecular variant of hairy cell leukemia with poor prognosis

(2011) Evgeny Arons et al.   LEUKEMIA & LYMPHOMA

Integrated genomic analyses of ovarian carcinoma

(2011) D. Bell et al.   NATURE

Melanoma epidemic: Facts and controversies

(2010) Corinne Erickson et al.   CLINICS IN DERMATOLOGY

Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer

(2010) Daniel J. Sargent et al.   JOURNAL OF CLINICAL ONCOLOGY

Rearrangement ofMYCIs Associated With Poor Prognosis in Patients With Diffuse Large B-Cell Lymphoma Treated in the Era of Rituximab

(2010) Sharon Barrans et al.   JOURNAL OF CLINICAL ONCOLOGY

Analysis of EPCAM Protein Expression in Diagnostics of Lynch Syndrome

(2010) Matthias Kloor et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunohistochemical Methods for Predicting Cell of Origin and Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab

(2010) Paul N. Meyer et al.   JOURNAL OF CLINICAL ONCOLOGY

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

(2010) Wendy De Roock et al.   LANCET ONCOLOGY

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

(2010) Poulikos I. Poulikakos et al.   NATURE

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

(2010) Eunice L. Kwak et al.   NEW ENGLAND JOURNAL OF MEDICINE

MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy

(2009) K. J. Savage et al.   BLOOD

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

(2009) Ronald P DeMatteo et al.   LANCET

Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type

(2009) Carlos A Torres-Cabala et al.   MODERN PATHOLOGY

Treatment for Patients With Unknown Primary Carcinoma and Unfavorable Prognostic Factors

(2009) F. Anthony Greco et al.   SEMINARS IN ONCOLOGY

Molecular Pathobiology of Gastrointestinal Stromal Sarcomas

(2008) Christopher L. Corless et al.   Annual Review of Pathology-Mechanisms of Disease

Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib

(2008) Kazuya Taniguchi et al.   CANCER SCIENCE

Carcinoma of unknown primary (CUP)

(2008) Nicholas Pavlidis et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors

(2008) Narasimhan P. Agaram et al.   GENES CHROMOSOMES & CANCER

Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

(2008) Rafael G. Amado et al.   JOURNAL OF CLINICAL ONCOLOGY

Stromal Gene Signatures in Large-B-Cell Lymphomas

(2008) G. Lenz et al.   NEW ENGLAND JOURNAL OF MEDICINE

K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer

(2008) Christos S. Karapetis et al.   NEW ENGLAND JOURNAL OF MEDICINE